Node-RADS在MRI上对卵巢癌淋巴结转移标准化评估的诊断效能
研究纳入2018年12月至2023年4月81例接受MRI和减瘤手术的卵巢癌患者,评估Node-RADS对淋巴结转移的诊断效能。结果显示质地改变标准敏感度84.6%、特异度78.7%,Node-RADS评分>3时敏感度73.1%、特异度97.8%,患者水平和淋巴结水平AUC分别为0.869和0.895。结论认为Node-RADS可作为卵巢癌淋巴结转移结构化报告的合适选择。
要点
- Node-RADS评分>3时特异度达97.8%,敏感度73.1%,约登指数0.71。
- 质地改变是各评估标准中表现最佳者,敏感度84.6%,特异度78.7%。
- 淋巴结水平Node-RADS评分1、2、3、4、5分对应转移发生率分别为3.2%、4.5%、13.0%、85.7%、86.7%。
核心结论
- Node-RADS可作为卵巢癌淋巴结转移结构化报告的合适选择,Node-RADS评分>3时对卵巢癌淋巴结转移的诊断效能令人满意。
研究设计与样本
- 回顾性研究纳入2018年12月至2023年4月81例接受MRI和减瘤手术的卵巢癌患者,以手术病理为参考标准评估Node-RADS对淋巴结转移的诊断效能。
诊断标准与关键数值
- 质地改变标准敏感度84.6%、特异度78.7%、约登指数0.63;Node-RADS评分>3时敏感度73.1%、特异度97.8%、约登指数0.71;患者水平AUC 0.869,淋巴结水平AUC 0.895。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The Node-RADS score was proposed and provided a standardized, comprehensive assessment of lymph nodes (LNs), accounting for both size and configuration criteria. This study aimed to evaluate the diagnostic performance of the Node-RADS in LN metastasis of ovarian cancer (OC).
METHODS: From December 2018 to April 2023, 81 OC patients who underwent MRI and debulking surgery were included. The likelihood of LN metastasis was assessed by the Node-RADS with MRI. The chi-square test and Fisher's exact test were used to assess the differences in size and configuration between LNs with and without metastasis. The diagnostic performance of Node-RADS and its different criteria for LN metastasis was assessed with receiver operating characteristic (ROC) and area under the curve (AUC).
RESULTS: Among all Node-RADS evaluation criteria, textural changes had the best performance with a sensitivity of 84.6%, a specificity of 78.7%, and a Youden's index of 0.63. At the LN level, the incidence of LN metastasis with Node-RADS scores 1, 2, 3, 4, and 5 was 3.2%, 4.5%, 13.0%, 85.7%, and 86.7%, respectively. The best performance in assessing LN status was observed at Node-RADS scores > 3, with sensitivity, specificity, and Youden's index of 73.1%, 97.8%, and 0.71, respectively. In addition, at the patient and LN levels, the AUC for Node-RADS assessment of LNs was 0.869 and 0.895, respectively.
CONCLUSION: Node-RADS could be an appropriate choice for structured reporting of LN metastasis in OC. The diagnostic performance of LN metastasis in OC at a Node-RADS score > 3 was satisfactory.
引用
- Liu Y, Zhang Y, Tan Y, et al. Diagnostic performance of Node-RADS on MRI for a standardized assessment of lymph node metastasis in ovarian cancer. Abdom Radiol (NY). 2025. PMID: 40810810. doi:10.1007/s00261-025-05134-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。